TNXP

Tonix Pharmaceuticals Holding Corp. [TNXP] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

TNXP Stock Summary

Top 10 Correlated ETFs

TNXP


Top 10 Correlated Stocks

TNXP


In the News

04:05 29 Mar 2024 TNXP

3 Mind-Blowing Stocks That Could Turn $1,000 Into $1 Million

Here's the deal with stocks to turn $1,000 into $1 million: if you want to play, you gotta pay. I'm not just talking about the price of the securities themselves.

02:12 29 Mar 2024 TNXP

3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond

In almost every situation, investors should stay away from penny stocks. They're extremely speculative and they tend to facilitate delusions of grandeur.

07:00 29 Mar 2024 TNXP

Tonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in January: Focus is on TNX-102 SL for the Management of Fibromyalgia Following Positive Topline Results in Second Pivotal Phase 3 Trial

TNX-102 SL is a Non-Opioid Analgesic that Demonstrated Daily Pain Reduction Over Placebo (Primary Endpoint, p = 0.00005) and Showed Positive Effects Across All Six Key Secondary Endpoints in Recently Reported Phase 3 Trial

07:00 29 Mar 2024 TNXP

Tonix Pharmaceuticals to Present at The National Academies Committee on the Current State of Research, Development, and Stockpiling of Smallpox Medical Countermeasures Public Meeting

CHATHAM, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Seth Lederman M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at the National Academies of Sciences, Engineering, and Medicine Committee on the Current State of Research, Development, and Stockpiling of Smallpox Medical Countermeasures public meeting on Thursday, December 14, 2023 via Zoom. Dr. Lederman will participate in a panel discussion on Vaccine Research & Development taking place from 2:00 - 2:45 p.m. ET.

07:00 29 Mar 2024 TNXP

Tonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in December

CHATHAM, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Tonix Management will present and host investor meetings at the following December investor conferences:

08:16 29 Mar 2024 TNXP

Tonix shares sink 29% on discontinued development on depression treatment

Shares of Tonix Pharmaceuticals TNXP fell Tuesday after the company said it would discontinue development of its treatment for major depressive disorder.

07:00 29 Mar 2024 TNXP

Tonix Pharmaceuticals to Present at the 2023 ThinkEquity Conference

CHATHAM, N.J., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the ThinkEquity Conference on Thursday, October 19, 2023, at 8:00 a.m. ET, and host investor meetings. The conference is being held at the Mandarin Oriental, New York in New York City.

09:17 29 Mar 2024 TNXP

Why Is Tonix Pharmaceuticals (TNXP) Stock Down 29% Today?

Tonix Pharmaceuticals (NASDAQ: TNXP ) stock is falling hard on Friday after the clinical-stage biopharmaceutical company priced a share offering. According to a press release from Tonix Pharmaceuticals, it has entered into a securities purchase agreement with certain healthcare institutional investors.

07:00 29 Mar 2024 TNXP

Tonix Pharmaceuticals to Present at the August Virtual Investor Summit

CHATHAM, N.J., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Gregory Sullivan, M.D., Chief Medical Officer of Tonix Pharmaceuticals, will present at the August 2023 Virtual Investor Summit on Thursday, August 24, 2023, at 10:00 a.m. ET.

02:08 29 Mar 2024 TNXP

Penny Stocks To Buy? 5 To Watch With Big News This Week

Investors often rely on stock market news to stay abreast of everything, ranging from low-cost penny stocks to industry giants such as Apple or Tesla. It's no secret that news can ignite excitement and skepticism in the blink of an eye, fueling speculation and thereby increasing market volatility.

TNXP Financial details

Company Rating
Neutral
Market Cap
27.96M
Income
-124.84M
Revenue
37.89M
Book val./share
7.88
Cash/share
0.45
Dividend
-
Dividend %
-
Employees
117
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
-0.04
Forward P/E
-0.17
PEG
0
P/S
0.49
P/B
0.04
P/C
0.48
P/FCF
-0.16
Quick Ratio
0.48
Current Ratio
1.77
Debt / Equity
0.01
LT Debt / Equity
0.01
-
-
EPS (TTM)
-8.2
EPS next Y
-1.26
EPS next Q
-0.82
EPS this Y
-93.71%
EPS next Y
-84.7%
EPS next 5Y
-114.76%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-31.72%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0%
Inst Trans
0%
ROA
-90%
ROE
-79%
ROC
-1.02%
Gross Margin
17%
Oper. Margin
-327%
Profit Margin
-329%
Payout
-2%
Shs Outstand
80.82M
Shs Float
80.81M
-
-
-
-
Target Price
-
52W Range
0.26-4.0
52W High
-
52W Low
-
RSI
25
Rel Volume
12.61
Avg Volume
1.42M
Volume
17.93M
Perf Week
-39.07%
Perf Month
-43.47%
Perf Quarter
-61.15%
Perf Half Y
-72.38%
-
-
-
-
Beta
2.29
-
-
Volatility
0.04%, 0.03%
Prev Close
-33.25%
Price
0.2182
Change
-37.57%

TNXP Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-16.05K-3.53K-106.54-51.2-3.22
Operating cash flow per share
-14.75K-3.32K-102.69-41.95-2.74
Free cash flow per share
-14.76K-3.32K-120.79-61.55-4.09
Cash per share
15.41K1.4K162.9599.23.36
Book value per share
14.56K1.17K185.32121.445.8
Tangible book value per share
14.49K1.16K185.07121.445.8
Share holders equity per share
14.56K1.17K185.32121.445.8
Interest debt per share
044.522.770.53-0.2
Market cap
7.15M1.88M64.32M129.68M87.2M
Enterprise value
-17.88M-9.01M-11.43M-48.03M-32.27M
P/E ratio
-0.27-0.07-1.28-1.41-0.76
Price to sales ratio
00000
POCF ratio
-0.3-0.07-1.32-1.72-0.89
PFCF ratio
-0.3-0.07-1.13-1.17-0.6
P/B Ratio
0.30.20.730.590.42
PTB ratio
0.30.20.730.590.42
EV to sales
00000
Enterprise value over EBITDA
0.680.310.230.520.29
EV to operating cash flow
0.750.340.240.640.33
EV to free cash flow
0.750.340.20.430.22
Earnings yield
-3.65-15.08-0.78-0.71-1.32
Free cash flow yield
-3.35-14.19-0.89-0.85-1.68
Debt to equity
00.040.0100
Debt to assets
00.020.0100
Net debt to EBITDA
0.950.381.51.931.07
Current ratio
9.812.728.968.717.19
Interest coverage
000014.17
Income quality
0.920.930.960.820.89
Dividend Yield
0.461.310.0100.08
Payout ratio
-0.13-0.09-0.010-0.06
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00.01000
Capex to operating cash flow
000.180.470.49
Capex to revenue
00000
Capex to depreciation
-0.11-0.65-317.19-706.14-38.43
Stock based compensation to revenue
00000
Graham number
72.53K9.64K666.5374.0220.49
ROIC
-1.12-2.82-0.56-0.42-0.56
Return on tangible assets
-1-1.97-0.51-0.38-0.51
Graham Net
14.01K790.94144.7187.952.9
Working capital
23.4M8.81M78.17M167.33M112.6M
Tangible asset value
23.54M9.3M87.53M218.6M207.18M
Net current asset value
23.4M8.81M77.45M166.87M112.27M
Invested capital
00.040.0100
Average receivables
509.5K768K4.32M7.68M7.88M
Average payables
1.35M2.24M3.83M8.94M10.68M
Average inventory
0-505.5K-4.32M-7.68M-7.88M
Days sales outstanding
00000
Days payables outstanding
19.4738.8733.2352.5226.27
Days of inventory on hand
0-12.8-55.11-30.55-26.19
Receivables turnover
00000
Payables turnover
18.759.3910.996.9513.89
Inventory turnover
0-28.51-6.62-11.95-13.94
ROE
-1.1-3.01-0.57-0.42-0.56
Capex per share
-3.69-2.11-18.11-19.6-1.35

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.2303.3400.26
Net income per share
-0.68-0.61-3.08-2.68-1.83
Operating cash flow per share
-0.56-0.36-3.25-2.21-1.53
Free cash flow per share
-0.77-0.44-3.62-2.38-1.64
Cash per share
3.341.967.12.420.45
Book value per share
5.463.3816.3213.277.88
Tangible book value per share
5.463.3816.3212.217.17
Share holders equity per share
5.463.3816.3213.277.88
Interest debt per share
0.040-0.080.120.08
Market cap
138.84M149.77M37.4M16.73M8.35M
Enterprise value
-256.4K30.3M-33.55M-7.62M2.59M
P/E ratio
-1.22-1-0.3-0.15-0.07
Price to sales ratio
14.2601.102.09
POCF ratio
-5.9-6.72-1.14-0.72-0.36
PFCF ratio
-4.29-5.55-1.02-0.66-0.33
P/B Ratio
0.610.720.230.120.07
PTB ratio
0.610.720.230.120.07
EV to sales
-0.030-0.9900.65
Enterprise value over EBITDA
0.01-0.930.990.27-0.09
EV to operating cash flow
0.01-1.361.020.33-0.11
EV to free cash flow
0.01-1.120.910.3-0.1
Earnings yield
-0.2-0.25-0.83-1.7-3.35
Free cash flow yield
-0.23-0.18-0.98-1.51-3.02
Debt to equity
000.010.010.01
Debt to assets
000.010.010.01
Net debt to EBITDA
4.743.652.090.870.2
Current ratio
11.337.196.42.781.77
Interest coverage
-48.5139.6718.9400
Income quality
0.810.710.820.84
Dividend Yield
00.02000
Payout ratio
0-0.06000
Sales general and administrative to revenue
0.7600.2200
Research and developement to revenue
2.2800.7805.28
Intangibles to total assets
0000.070.08
Capex to operating cash flow
0.370.210.120.080.08
Capex to revenue
-0.910-0.110-0.45
Capex to depreciation
-35-5.59-4.25-2-1.49
Stock based compensation to revenue
0.2800.0800.52
Graham number
9.116.7933.6328.2817.99
ROIC
-0.13-0.18-0.19-0.41-0.22
Return on tangible assets
-0.12-0.17-0.17-0.19-0.22
Graham Net
3.011.695.751.25-0.24
Working capital
137.8M112.6M70.65M32.89M13.6M
Tangible asset value
228.92M207.18M165.43M129.28M109.89M
Net current asset value
137.42M112.27M70.07M32.06M12.89M
Invested capital
000.010.010.01
Average receivables
04.02M4.02M0781K
Average payables
7.06M6.31M8.04M7.84M7.74M
Average inventory
0-4.02M-4.02M6.85M13.51M
Days sales outstanding
000035.24
Days payables outstanding
1.63K868.56807.8823.81295.67
Days of inventory on hand
0-865.87042.51504.86
Receivables turnover
00002.55
Payables turnover
0.060.10.113.780.3
Inventory turnover
0-0.102.120.18
ROE
-0.12-0.18-0.19-0.2-0.23
Capex per share
-0.21-0.08-0.37-0.17-0.12

TNXP Frequently Asked Questions

What is Tonix Pharmaceuticals Holding Corp. stock symbol ?

Tonix Pharmaceuticals Holding Corp. is a US stock , located in Chatham of Nj and trading under the symbol TNXP

What is Tonix Pharmaceuticals Holding Corp. stock quote today ?

Tonix Pharmaceuticals Holding Corp. stock price is $0.2182 today.

Is Tonix Pharmaceuticals Holding Corp. stock public?

Yes, Tonix Pharmaceuticals Holding Corp. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap